Immunai, a biotech start-up founded by MIT, Harvard and Stanford researchers, has emerged from stealth mode with $20 million in seed funding to accelerate efforts to map out immune systems using machine learning.
The start-up, founded by former Harvard University postdoctoral researcher, Noam Solomon, and Louis Voloch, previously a ML engineer at Palantir, combines single cell genomics with ML algorithms to create high resolution profiles of immune cells from blood samples. The proprietary platform can support biomarker discovery and aid immunotherapy and cell therapy development. According to Immunai, their dataset is the world’s largest for clinical immunological data.
The substantial seed funding, led by Viola Group and TLV Partners, will be put towards expanding the company’s team of scientists, engineers and ML specialists, as well as advancing product development.
CEO, Noam Soloman, explained that their end-to-end platform, by utilising ML, provides a more comprehensive, holistic understanding of immunological systems:
“When looking at only a specific disease or patient cohort, one gets a limited and siloed view of the immune system. By using ML and applying it to our proprietary diverse database of single-sequencing data paired with rich clinical data, our platform identifies common patterns that are not visible when looking at the narrower disease-specific view.”